biostudies-literatureUnknown39(21)Reck M<h4>Purpose</h4>We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no sensitizing <i>EGFR</i> or <i>ALK</i> alterations. Previous analyses showed pembrolizumab significantly improved progression-free survival and overall survival (OS).<h4>Methods</h4>Eligible patients were randomly assigned (1:1) to pembrolizumab (200 mg once every 3 weeks for up to 35 cycles) or platinum-based chemotherapy. Patients in the chemotherapy group with pJournal of clinical oncology : official journal of the American Society of Clinical Oncology2339-2349https://www.ebi.ac.uk/biostudies/studies/S-EPMC8280089biostudies-literatureFive-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.PMC8280089Rao SReck MHui RBrahmer JRCsoszi TZhao BHotta KRodriguez-Abreu DPeled NGottfried MJensen ETafreshi ARiess JWPietanza MCO'Brien MLeal TACuffe SRobinson AGFulop AfalseFive-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.<h4>Purpose</h4>We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no sensitizing <i>EGFR</i> or <i>ALK</i> alterations. Previous analyses showed pembrolizumab significantly improved progression-free survival and overall survival (OS).<h4>Methods</h4>Eligible patients were randomly assigned (1:1) to pembrolizumab (200 mg once every 3 weeks for up to 35 cycles) or platinum-based chemotherapy. Patients in the chemotherapy group with p2021-01-01T00:00:00Z2021 Jul2025-04-04T22:12:13.951Z2025-04-04T22:12:13.951ZS-EPMC82800893387207010.1200/JCO.21.00174